Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 4, 2015
Pharmacy Choice - News - Pharmaceutical Development - July 4, 2015

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/4/15 - IP scene [China Daily: Hong Kong Edition]
China, US hold simulated IP court. It has been used as a cancer treatment in China since 1995 and is the first TCM injection treatment to undergo the FDA approval process. Last week, an IP training program was held in Qingdao for South Korean companies with offices in China.
7/3/15 - AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies [New Vision (Uganda)]
-AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors, announces that the external Data and Safety Monitoring Board has recently recommended, based upon updated safety and efficacy data, continuation of three on-going phase 2 studies assessing masitinib, one in second-line treatment
7/3/15 - Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer [Cihan News Agency (Turkey)]
The acceptance of this IND allows Adaptimmune to initiate an open label Phase I/II study designed to evaluate its wholly-owned MAGE-A10 T therapeutic candidate in NSCLC. Adaptimmune's proprietary technology enables the Company to routinely generate TCRs which address intracellular targets, such as MAGE-A10, that are not accessible to certain other.
7/3/15 - Approval for manufacture and sale of XIAFLEX (collagenase clostridium histolyticum) in Japan
Asahi Kasei Pharma today obtained approval for the manufacture and sale of XIAFLEX* injection for the treatment of Dupuytren's contracture in Japan. Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement concluded in March 2011. After conducting a Phase III clinical trial in Japan, Asahi Kasei Pharma filed an
7/3/15 - Derma Sciences Announces Medicare Coverage Reinstated For MEDIHONEY Products with Reimbursable Codes by Centers for Medicare & Medicaid Services
By a News Reporter-Staff News Editor at Insurance Weekly News Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, announces that the Centers for Medicare& Medicaid Services has reinstated coverage and assigned a reimbursable code for MEDIHONEY dressings effective immediately. Edward J. Quilty, Chairman
7/3/15 - Dr. Pierre-Andre Wicker joins Pharmaleads' Board of Directors [Global Data Point]
Pierre-Andr Wicker has spent most of his career in the pharmaceutical industry in the United States. Having spent five years working for the Cleveland Clinical Foundation, in 1989 he joined Pfizer, where he was responsible for major drug development programs, from early-stage development to phase III, in the fields of cardiovascular pathologies a
7/3/15 - Dr. Pierre-Andre Wicker joins Pharmaleads' Board of Directors [Moj News Agency (Iran)]
Pierre-Andr Wicker is joining the Company's Board of Directors. Pierre-Andr Wicker has spent most of his career in the pharmaceutical industry in the United States. Having spent five years working for the Cleveland Clinical Foundation, in 1989 he joined Pfizer, where he was responsible for major drug development programs, from early-stage devel
7/3/15 - Ebola vaccine trial is not dangerous Prof Binka [Ghana News Agency]
The vaccine against the Ebola viral disease, being tested by the Kintampo Health Research Centre and now under clinical trials is not dangerous to the health and well-being of the public. Kintampo, July 3, GNA- The vaccine against the Ebola viral disease, being tested by the Kintampo Health Research Centre and now under clinical trials is not dange
7/3/15 - Encouraging results for gene therapy trial for CF
A therapy that replaces the faulty gene responsible for cystic fibrosis in patients' lungs has produced encouraging results in a major UK trial. Patients from across England and Scotland participated, and were treated in two centres, Royal Brompton Hospital in London and the Western General Hospital in Edinburgh. The study was carried out by the UK
7/3/15 - Epizyme to Participate at the European Cancer Congress [Manufacturing Close - Up]
Epizyme reported that updated data from the phase 1 portion of its ongoing phase 1/ 2 study of tazemetostat will be presented during the European Cancer Congress 2015, hosted by the European Society of Medical Oncology, to be held in Vienna, Austria, September 25- 28. In a release, the Company noted that tazemetostat is a first-in- class EZH2 inhib
7/3/15 - First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder [Palestine Chronicle, The]
-Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders today announced that the first patient has been dosed in an investigator sponsored trial of the Company's oral cyclin dependent kinase inhibitor selicicli
7/3/15 - Gene therapy for cystic fibrosis shows encouraging trial results [Global Data Point]
Patients from across England and Scotland participated, and were treated in two centres, Royal Brompton Hospital in London and the Western General Hospital in Edinburgh.&# x0D;. The study was carried out by the UK Cystic Fibrosis Gene Therapy Consortium, a group of scientists and clinical teams from Imperial College London, the Universities of Oxfo
7/3/15 - IGI Laboratories Submits Fifth ANDA Submission of 2015 [Health & Beauty Close - Up]
New Jersey- based IGI Laboratories on June 30 reported that it has submitted its fifth abbreviated new drug application to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-seven. Jason Grenfell-Gardner, President and CEO of the Company, commented, "We believe
7/3/15 - Johnson & Johnson -Investigational HIV Vaccine Regimen Shows Encouraging Results in Non-Human Primates
Release date- 02072015- NEW BRUNSWICK, N.J.,- Johnson& Johnson announced today that scientists at Beth Israel Deaconess Medical Center, Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson& Johnson, and several other collaborators today published results from a preclinical study of an HIV vaccine regimen used in in non-human
7/3/15 - Oncodesign Raises USD17.8 Million in IPO
Deal Type: Equity Offerings Deal Sub Type: IPO Deal Country: France Deal Status: Completed Deal Value: 17.7597 USD. Oncodesign SA, a drug discovery company, has completed the initial public offering of 1,749,394 shares of its common stock at a price of EUR7.34 per share, for gross proceeds of EUR12.8 million. CM-CIC Securities SA acted as book runn
7/3/15 - Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ (tofacitinib citrate) Modified Release Tablets
Release date- 02072015- Pfizer Inc. announced today that the United States Food and Drug Administration accepted for review Pfizer's new drug application for XELJANZ 11 mg once daily modified release tablets for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response or intolerance to methotrexate.
7/3/15 - Progress in clinical trials for the FDA application for The NGAL Test? and launch of new generic strip test
BioPorto has conducted a preliminary internal assessment of the data from the completed clinical trials in the USA. The preliminary internal assessment of data support the further application process, including the formulation of the application, which is expected to be submitted to the FDA in September 2015 at the latest. BioPorto has in licensed
7/3/15 - Reports on Drug Discovery from University of Cambridge Provide New Insights (Using transcriptomics to guide lead optimization in drug discovery...
For more information on this research see: Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project. Drug Discovery Today, 2015; 20: 505-513. Drug Discovery Today can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1 GB, Oxon, England. Our news journa
7/3/15 - University of Bologna Details Findings in Clinical Research (Clinical Evaluation of Zirconia-Based Restorations on Implants: A Retrospective Cohort...
University of Bologna Details Findings in Clinical Research. According to news originating from Bologna, Italy, by NewsRx correspondents, research stated, "The aim of this retrospective cohort study was to evaluate the clinical performance of zirconia-based implant-supported single crowns and fixed dental prostheses made by 15 members of the Italia
7/3/15 - Vertex drug gets FDA approval [Boston Herald]
July 03 The Food and Drug Administration yesterday approved Vertex Pharmaceuticals' latest cystic fibrosis drug, offering new hope for about 8,500 of the 30,000 Americans who suffer from the life-threatening genetic disease. "I was driving home from work when the news popped up on my phone, and I started bawling; I called my dad and said,' Thank
7/3/15 - Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of... [Daily News Egypt]
-Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that they have begun approving clinical trial centers for participation in its pivotal Phase 3 human clinical trial for Vicinium?. Based on discussions with the U.S. Food and Drug Administration, Viventia has finalized its cli
7/3/15 - VRTX Drug Gets Approval, AGTC Surges On Biogen Deal, PFE Gets A Date With FDA
WESTON- Adaptimmune Therapeutics plc is all set to initiate an open label phase I/II study of its wholly-owned MAGE-A10 T therapeutic candidate in patients with non-small cell lung cancer, following the acceptance of the company's investigational new drug application by the FDA. Shares of Applied Genetic Technologies Corp. surged over 17% on Thursd
7/2/15 - AB Science: the Data and Safety Monitoring Board recommends continuation of three phase 2 studies
AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors, announces that the external Data and Safety Monitoring Board has recently recommended, based upon updated safety and efficacy data, continuation of three on-going phase 2 studies assessing masitinib, one in second-line treatmen
7/2/15 - Adapt Pharma Acquires Narcan NDA and Obtains License to the Narcan Trademark
Adapt Pharma Limited announced today that it has obtained a license to the Narcan trademark and acquired the related Narcan New Drug Application. Adapt Pharma previously announced that it had commenced a rolling submission of an NDA to the FDA for a nasal spray formulation of naloxone, a drug intended to treat opioid overdose. Use of the Narcan nam
7/2/15 - Adaptimmune Announces FDA Acceptance of Investigational New Drug (IND) Application for MAGE-A10 T in Patients With Non-Small Cell Lung Cancer
The acceptance of this IND allows Adaptimmune to initiate an open label Phase I/II study designed to evaluate its wholly-owned MAGE-A10 T therapeutic candidate in NSCLC. Adaptimmune's proprietary technology enables the Company to routinely generate TCRs which address intracellular targets, such as MAGE-A10, that are not accessible to certain other.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415